PharmaMar und Boryung Pharm Sign gehen einen Lizenzvertrag über Aplidin® (Plitidepsin) in Korea ein .
Published: 2016-10-04 14:14Updated: 2016-10-04 14:14
Boryung Pharmaceutical(003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.
By Yun Jeong-hyeon